Fujirebio Holdings’ portfolio of biomarkers and diagnostic tools for Parkinson’s disease now includes tailor-made antibodies against the protein alpha-synuclein with the company’s acquisition of ADx NeuroSciences. The $40 million acquisition is expected to be complete in July, pending the satisfaction of customary closing conditions.
Supernus Pharmaceuticals’ portfolio of Parkinson’s disease therapies now includes Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride), with the company’s acquisition of Adamas Pharmaceuticals now complete. “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” Jack Khattar, president and CEO of Supernus…
Parkinson’s vaccine candidate Affitope PD01, along with maker Affiris’ portfolio of other alpha-synuclein-targeting therapies, was acquired by AC Immune in a recent deal valued at nearly $60 million. “We believe very strongly that active vaccination will play an important role in the long-term management and possible prevention of…
Adamas Pharmaceuticals has acquired global rights to the Parkinson’s disease medication Osmolex ER (amantadine hydrochloride), used to treat motor symptoms, including those caused by other therapies. The purchase, worth $7.5 million, was part of a settlement agreement with the medicine’s developer, Osmotica Pharmaceutical US, according to a…
Biogen is adding Pfizer’s PF-05251749 — a regulator of the body’s inner clock — to its group of potential disease-modifying therapies for Parkinson’s and Alzheimer’s diseases. Biogen plans to test PF-05251749 in an upcoming Phase 1 clinical trial as a treatment to correct irregular sleep wake…
Lundbeck will acquire the biopharmaceutical Prexton Therapeutics, obtaining the development and commercialization rights to foliglurax (PTX002331), an investigational therapy currently in Phase 2 trials for Parkinson’s disease. Foliglurax is a small molecule modulator that activates nerve cells with a set of specific glutamate receptors called mGluR4, and compensates…
Get regular updates to your inbox.
